Looking forward to Global Blood Therapeutics report out of Part A from their Phase 3 Hope study of their drug voxelotor (formerly GBT440) in patients with sickle cell disease. Data should come any day now and it will be exciting to see if the 1500 mg dose improves on the prior excellent data for the 900 mg dose. Prior data for this drug in this indication where there is an overwhelming need for major advances over current therapies has led to FDA Fast Track, Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations. Pullback in stock price from highs in earlier 2018 has led to an opportunity for investors leading into this important readout.
top of page
bottom of page